here's some info re the presentation that IPD are doing at the ASBS meeting thats on now.. ( from IPD web site ) PB and the sales force/medical are there to work on as many leads/contacts as possible.. update on coming 4c I suspect..
the study being presented at ASBS is part of further work/analysis from the PREVENT trial.. as Acclivity says.. there is a better way ... and that is now building..New research shows patients at risk of developing breast cancer-related lymphedema should be monitored for minimum of three years following completion of cancer treatment
t
CARLSBAD, Calif., April 11, 2024 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, announced today that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on Friday, April 12, 2024.
The study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," revealed that patients at risk of developing breast cancer related lymphedema (BRCL) should continue to be monitored for three years following the completion of cancer treatment, as patients could trigger at any time over this period.
"Chronic breast cancer-related lymphedema can represent a risk to patients who have undergone breast cancer treatment with meaningful impact on their quality of life," said Chirag Shah, MD, Co-Director of the Comprehensive Breast Cancer Program, Cleveland Clinic, lead author of the study, and scientific adviser to ImpediMed. "Early detection and intervention are critical to preventing chronic lymphedema. The intent of our analysis was to illustrate that patients can develop breast cancer-related lymphedema from a few months to a few years after treatment, emphasizing the need for careful screening for years following treatment."
The results are part of PREVENT, the largest randomized control trial to assess lymphedema prevention, in 1200 women, which monitored progression to BCRL following intervention for BCRL assessed by both bioimpedance spectroscopy (BIS) and a tape measure, demonstrating lower progression to chronic lymphedema with early detection using BIS and intervention versus using tape measure.
ImpediMed Chief Medical Officer, Steven L. Chen, MD, MBA, one of the study's authors, will present the findings at ASBrS.
"This study confirms that patients continue to be at risk for developing BCRL years after treatment and thus may continue to progress to chronic breast cancer-related lymphedema (cBCRL) even 3 years after surgery," said Chen. "We look forward to discussing this important research with our colleagues in Orlando."
4c soon.. usual anticipation..
cheers ..
